Emerging Advances in the Management of Cardiac Amyloidosis

Current Cardiology Reports

Volumn 17, Issue 11, 2015, Pages

  Vranian, Michael N ^a   Sperry, Brett W ^a   Valent, Jason ^a   Hanna, Mazen ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cardiac amyloidosis; Heart transplant; Light chain; Transthyretin

Indexed keywords

ALN TTR 01; AMYLOID; ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIFLUNISAL; DIURETIC AGENT; DOXYCYCLINE; EPIGALLOCATECHIN GALLATE; FLUFENAMIC ACID; GSK 2315698A; IXAZOMIB; LENALIDOMIDE; MELPHALAN; MONOCLONAL ANTIBODY; NEOD 001; PATISIRAN; PLACEBO; POMALIDOMIDE; PREDNISONE; REVUSIRAN; SMALL INTERFERING RNA; TAFAMIDIS; TAUROURSODEOXYCHOLIC ACID; THALIDOMIDE; UNCLASSIFIED DRUG; GLUCOCORTICOID; IMMUNOGLOBULIN LIGHT CHAIN;

AUTOLOGOUS STEM CELL TRANSPLANTATION; DISEASE CLASSIFICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FAMILIAL AMYLOID POLYNEUROPATHY; GENE SILENCING; HEART AMYLOIDOSIS; HEART TRANSPLANTATION; HUMAN; LIGHT CHAIN AMYLOIDOSIS; NEUROTOXICITY; NONHUMAN; REVIEW; SINGLE DRUG DOSE; TRANSTHYRETIN CARDIAC AMYLOIDOSIS; UNSPECIFIED SIDE EFFECT; AMYLOID NEUROPATHIES, FAMILIAL; AMYLOIDOSIS; CARDIOMYOPATHIES; PROCEDURES; STEM CELL TRANSPLANTATION;

AMYLOID NEUROPATHIES, FAMILIAL; AMYLOIDOSIS; BORTEZOMIB; CARDIOMYOPATHIES; GLUCOCORTICOIDS; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; STEM CELL TRANSPLANTATION;

EID: 84941961047     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-015-0653-1     Document Type: Review

References (68)

1. Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc. 2012;60(4):765–74.
2. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7:398–408.
3. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047–60.
4. Molina OG, Judge D, Campbell W, Cahal H, Mugmon M. Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure. J Community Hosp Intern Med Perspect. 2014;4(5):25500.
5. Poshusta TL, Sikkink LA, Leung N, et al. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS ONE. 2009;4(4), e5169.
6. Leinonen H, Pohjola-Sintonen S. Cardiac amyloidosis. Therapeutic and diagnostic difficulties with reference to two different forms of the disease. Acta Med Scand. 1986;219(1):125–8.
7. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9. Important trial updating the Mayo prognostic criteria for amyloidosis with serum free light chain assessment.
8. Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426–30.
9. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79(4):319–28. Most recent consensus document on defining organ involvement in amyloidosis.
10. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336(17):1202–7.
11. Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2014;99(4):743–50.
12. Gertz MA, Lacy MQ, Dispenzieri A, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48(4):557–61.
13. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case–control study. Blood. 2004;103(10):3960–3.
14. Sanchorawala V, Skinner M, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110(10):3561–3.
15. Kastritis E, Roussou M, Gavriatopoulou M, et al. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015;90(4):E60–5.
16. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387–90.
17. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391–4.
18. Zonder JA, Sanchorawala V, Snyder RM, et al (2009) Melphalan and dexamethasone plus bortezomib induces hematologic and organ responses in al-amyloidosis with tolerable neurotoxicity. Blood (ASH Annual Meeting Abstracts) 114: Abstract 746
19. Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014;99(2):209–21.
20. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121:5124–30.
21. Conner R, Hosenpud JD, Norman DJ, et al. Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease. J Heart Transplant. 1988;7(2):165–7.
22. Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation. 1991;84(5S):III338–43.
23. Dubrey SW, Burke MM, Hawkins PN, et al. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004;23(10):1142–53.
24. Kpodonu J, Massad MG, Caines A, et al. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant. 2005;24(11):1763–5.
25. Lacy MQ, Dispenzieri A, Hayman SR, et al. Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. J Heart Lung Transplant. 2008;27(8):823–9.
26. Dey BR, Chung SS, Spitzer TR, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010;90:905–11.
27. Gilstrap LG, Niehaus E, Malhotra R, et al. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J Heart Lung Transplant. 2014;33(2):149–56.
28. Wall JS, Kennel SJ, Williams A, et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS ONE. 2012;7(12), e52686.
29. Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012;119(23):5397–404.
30. Zonder J, Houde C, Tuchman S, et al. A phase I trial of pomalidomide, bortezomib (Velcade), and dexamethasone (PVD) as initial treatment of AL amyloidosis and light chain deposition disease. Blood (ASH Annu Meet Abstr). 2014;124:4767.
31. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336(7):466–73.
32. Yamashita T, Hamidi AK, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid. 2005;12(2):127–30.
33. Buxbaum J et al. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol. 2006;47(8):1724–5.
34. Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991;40:242–6.
35. Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl. 2015;21:282–92.
36. Hamour IM, Lachmann HJ, Goodman HJB, et al. Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant. 2008;8(5):1056–9.
37. Roig E, Almenar L, Gonzalez-Vilchez F, et al. Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant. 2009;9(6):1414–9.
38. Ammirati E, Marziliano N, Vittori C, et al. The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation. Amyloid. 2012;19(2):113–7.
39. Thenappan T, Fedson S, Rich J, et al. Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis. Amyloid. 2014;21(2):120–3.
40. Baures PW, Peterson SA, Kelly JW. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem. 1998;6:1389. This article and the next two from the lab of Dr. Kelly are excellent examples of years of basic science research translating into breakthrough therapy.
41. Munro SL, Lim CF, Hall JG, et al. Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine binding globulin. J Clin Endocrinol Metab. 1989;68:1141–7.
42. Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol. 2000;7:312–21.
43. Stone CA, Van Arman CG, Lotti VJ, et al. Pharmacology and toxicology of diflunisal. Br J Clin Pharmacol. 1977;4(Suppl1):19S–29.
44. Berk JL, Suhr OB, Obici L, et al. Diflunisal trial C. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–67. This is the only randomized placebo-controlled trial in transthyretin amyloidosis that has met its primary endpoint. This landmark clinical trial will likely lead to the approval of diflunisal for the indication of FAP.
45. Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109:9629–34.
46. Giampaolo M, Plante-Bordeneuve P, Judge DJ, et al. Effect of tafamidids on transthyretin stabilization and clinical outcomes in patients with Non-Val30MET transthyretin amyloidosis. J Cardiovasc Trans Res. 2013;6:1011–20.
47. Coelho T, Maia LF, da Silva AM, et al. Tafamidis for transthyretin familial amyloid polyneuropathy. Neurology. 2012;79(8):785–92. This was the first randomized placebo-controlled trial in transthyretin amyloidosis. Although the primary endpoint was not met, the results led to the approval of tafamidis in Europe.
48. Damy T, Judge DP, Kristen AV, et al. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Trans Res. 2015;88:117–27.
49. Maurer M, Grogan D, Judge D, et al. Tafamidis in transthyretin amyloid cardiomyopathy effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015;8:519–26.
50. Ferreira N, Cardoso I, Domingues MR, et al. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett. 2009;583:3569–76.
51. Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012;101:805–13.
52. Siepen FA, Buss SJ, Andre F, et al. Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of t1 mapping by cardiac magnetic resonance imaging in a small single center study. Clin Res Cardiol. 2015;104(8):640–7.
53. Mereles D, Buss SJ, Hardt SE, et al. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with al amyloidosis. Clin Res Cardiol. 2010;99:483–90.
54. Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12:329–40.
55. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259–93.
56. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819–29. This is a major breakthrough and publication in the field. A New England Journal of Medicine publication has brought transthyretin amyloidosis into greater awareness amongst physicians.
57. Coelho T, Suhr O, Coneicau I, et al. Phase 2 open-label extension study of patisiran, an investigational RNAi therapeutic for the treatment of familial amyloid polyneuropathy. Neurology. 2015;84(14):S9.003.
58. Gagnon KT, Watts JK, On behalf of the Board of the Oligonucleotide Therapeutics Society. 10th Annual Meeting of the Oligonucleotide Therapeutics Society: session summary. Nucleic Acid Ther. 2014;24(6):428–34.
59. Ackerman EJ, Guo S, Booten S, et al. Clinical development of antisense therapy for the treatment of transthryetin-associated polyneuropathy. Amyloid. 2012;19(S1):43–4.
60. Tagliavini F, Forloni G, Colombo L, Salmona M, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol. 2000;300:1309–22.
61. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 2006;20:234–9.
62. Ward JE, Ren R, Toraldo G, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011;118:6610–7.
63. Rodrigues CM, Sola S, Brito MA, et al. Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate. Biochem Biophys Res Commun. 2001;281:468–74.
64. Sola S, Castro RE, Laires PA, et al. Tauroursodeoxycholic acid prevents amyloid beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med. 2003;9:226–34.
65. Macedo B, Batista AR, Ferreira N, et al. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biochim Biophys Acta. 1782;2008:517–22.
66. Cardoso I, Martins D, Ribeiro T, et al. Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8:74.
67. Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012;19(S1):34–6.
68. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468:93–7. Landmark trial in Nature demonstrating the first pharmaceutical able to directly target amyloid deposits for enhanced clearance.